Agilent Technologies, Inc. (A)
Agilent Technologies, Inc. (A) is a healthcare company (diagnostics & research) based in the United States. The share price is $172.66, down 0.15% on the day, which values the company at $48.68B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.
Key facts
- Share price
- $172.66−0.15% today
- Market value
- $48.68B
- P/E ratio
- 34.1×last 12 months
- Forward P/E
- 25.7×
- Dividend yield
- 0.59%
- Funk Score
- 55/100
- Against its own history
- Well above its usual priceusual price $105.64
- 200-week average
- $132.6130% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Agilent Technologies, Inc. in more detail
A trades at 34.1× its last twelve months' earnings, 25.7× next year's expected earnings, 6.6× sales. Measured against its own history, the price is 63% above what its usual multiples would imply ($105.64) — well above its usual price. It sits 30% above its 200-week average of $132.61.
Over the last five fiscal years Agilent Technologies, Inc. has compounded revenue 5.4% a year, earnings per share 14.7% a year, free cash flow 7.5% a year. Its Funk Score is 55 out of 100 (financial strength 7.4, profitability 7.2, growth 4.5, value 2.9, each out of 10).
In its favour: Altman Z in the safe zone; Share count keeps falling.
4 of the superinvestors tracked here hold A, including Larry Robbins (5.2% of the portfolio), Cliff Asness (0.2% of the portfolio), Primecap team (0.1% of the portfolio).
Superinvestors holding A
4 of the investors tracked here report a position in their latest 13F filing.
- Larry Robbins Glenview Capital Management5.23% of portfolio · $261.6M · new · Q2 2026
- Cliff Asness AQR Capital Management0.17% of portfolio · $472.4M · added · Q2 2026
- Primecap team Primecap Management0.14% of portfolio · $228.1M · trimmed · Q3 2026
- Edgar Wachenheim Greenhaven Associates0.02% of portfolio · $1.8M · Q3 2026
Health Care companies of similar size
- Cardinal HealthCAH
- argenxARGX
- Edwards LifesciencesEW
- Becton, DickinsonBDX
- IDEXX LaboratoriesIDXX
- MedlineMDLN
- HumanaHUM
- Teva Pharmaceutical IndustriesTEVA
- BeOne MedicinesONC
- WatersWAT
- NateraNTRA
- IQVIA HoldingsIQV
Side by side:A vs TEVA (Agilent Technologies, Inc. vs Teva Pharmaceutical Industries)A vs HUM (Agilent Technologies, Inc. vs Humana)A vs MDLN (Agilent Technologies, Inc. vs Medline)A vs ONC (Agilent Technologies, Inc. vs BeOne Medicines)A vs IDXX (Agilent Technologies, Inc. vs IDEXX Laboratories)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Agilent Technologies, Inc. (A): questions and answers
What is A's P/E ratio?
Agilent Technologies, Inc. trades at 34.1× its last twelve months' earnings and 25.7× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 7.9× to 66.8×, with a median of 27.0×.
What is A's PEG ratio?
Agilent Technologies, Inc.'s PEG ratio is 1.47 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Agilent Technologies, Inc.'s market cap?
Agilent Technologies, Inc. is valued at $48.68B at a share price of $172.66.
Is A overvalued or undervalued?
Against its own history, A is well above its usual price: the price is 63% above the $105.64 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is A above its 200-week moving average?
Yes. A is 30.2% above its 200-week average of $132.61. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Agilent Technologies, Inc. growing?
Over the last five fiscal years Agilent Technologies, Inc.'s revenue grew 5.4% a year and its earnings per share 14.7% a year; over ten years revenue grew 5.6% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Agilent Technologies, Inc. (A) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/A
Underlying data: Yahoo Finance; company filings with the SEC.